Bausch Health Q2 2021 Earnings Report
Key Takeaways
Bausch Health Companies Inc. announced its second-quarter 2021 financial results, demonstrating impressive overall company growth as businesses continue to recover from the COVID-19 pandemic. Total reported revenues were $2.100 billion, an increase of 26% compared to the second quarter of 2020. The company reported a GAAP net loss of $595 million and Adjusted EBITDA of $826 million.
Revenues of $2.100 Billion
GAAP Net Loss of $595 Million
Adjusted EBITDA (non-GAAP) of $826 Million
GAAP Cash Generated from Operations of $395 Million
Bausch Health
Bausch Health
Bausch Health Revenue by Segment
Forward Guidance
Bausch Health revised its revenue and Adjusted EBITDA (non-GAAP) guidance ranges for the full year of 2021, primarily due to the divestiture of Amoun Pharmaceutical Company S.A.E., the impact of a recall of certain Consumer products due to a quality issue at a third-party supplier and the negative impact of foreign exchange:
Positive Outlook
- Full-year revenue range of $8.40 – $8.60 billion
- Full-year Adjusted EBITDA (non-GAAP) range of $3.35 – $3.50 billion
Revenue & Expenses
Visualization of income flow from segment revenue to net income